Christopher Lu's questions to HOOKIPA Pharma (HOOK) leadership • Q4 2020
Question
Christopher Lu of SVB Leerink inquired about the upcoming AACR presentation, asking if preliminary efficacy data for the alternating dose regimen would be shared, how to interpret the read-through from immunogenicity to efficacy, and if multiple clinical updates for the alternating regimen were planned.
Answer
Igor Matushansky, Chief Medical Officer, clarified that the AACR presentation will focus exclusively on translational data, with clinical efficacy updates reserved for the ASCO conference in June. He explained that based on preclinical data, improved immunogenicity is expected to translate to improved efficacy. Matushansky confirmed that clinical efficacy for both the HB-201 and HB-201/HB-202 programs would be updated at ASCO.